Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “overweight” rating restated by research analysts at Piper Jaffray Companies in a report issued on Thursday. They presently have a $55.00 target price on the biotechnology company’s stock, up from their prior target price of $50.00. Piper Jaffray Companies’ target price points to a potential upside of 27.88% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Royal Bank Of Canada restated a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. set a $76.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 8th. Nomura restated a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, May 23rd. Finally, Vetr downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price on the stock. in a research report on Monday, May 15th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $62.31.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 43.01 on Thursday. Sarepta Therapeutics has a 1-year low of $25.47 and a 1-year high of $63.73. The firm has a 50-day moving average price of $39.34 and a 200-day moving average price of $34.16. The company’s market cap is $2.77 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. The business’s revenue was up 350000.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.19) EPS. On average, equities analysts expect that Sarepta Therapeutics will post ($1.23) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/09/sarepta-therapeutics-inc-srpt-rating-reiterated-by-piper-jaffray-companies.html.

In other news, SVP Alexander Cumbo sold 5,918 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the completion of the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at $934,513. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandesh Mahatme sold 50,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at $1,711,176. The disclosure for this sale can be found here. Insiders sold 78,056 shares of company stock valued at $3,224,208 over the last ninety days. Insiders own 9.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Prentiss Smith & Co. Inc. boosted its holdings in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares during the period. Ameritas Investment Partners Inc. purchased a new position in Sarepta Therapeutics in the first quarter valued at $127,000. Cubist Systematic Strategies LLC boosted its holdings in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,800 shares during the period. Finally, Edge Wealth Management LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at $175,000. Hedge funds and other institutional investors own 65.43% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.